Effect of a Brief Mood Training Program on Anxiety and Depression Arising from COVID-19-Related Stress

Not Applicable

Completed

• Conditions: Depression; Anxiety; COVID-19; Mental Health - Depression; Mental Health - Anxiety; Infection - Other infectious diseases; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12620000811909
• Lead Sponsor: SW Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-13
• Study Completion: 2022-02-18
• Last Update Posted: 17 April 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 174

Inclusion Criteria

Inclusion Criteria:
• Score of greater than or equal to 16 on K10
• Aged at least 18 years
• Sufficient English language comprehension
• Access to teleconferencing platform

Exclusion Criteria

Exclusion Criteria:
• Current psychosis
• Imminent suicidal risk
• Current substance dependence (but not abuse)
No access to internet-based access to teleconferencing facility

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anxiety and depression represent a composite primary outcome, as measured by the Hospital Anxiety and Depression scale.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 20).]

Secondary Outcome Measures

Name	Time	Method
Positive and negative affect as measured by the Positive and Negative Affect Scale.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 20).];Health related quality of life will be measured using Australian Quality of Life.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 20).];Sleep difficulties as measured by the Sleep Impairment Index.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 20).];Pandemic related concerns as measured by the Coronavirus Concerns Scale.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 20).];Worry as measured by the Generalized Anxiety DIsorder 7.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 20).];Suicidal ideation as measured by the Suicide Attribute Scale.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 20).]